199 related articles for article (PubMed ID: 21792569)
1. A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).
van Dodewaard-de Jong JM; de Klerk JM; Bloemendal HJ; van Bezooijen BP; de Haas MJ; Wilson RH; O'Sullivan JM
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1990-8. PubMed ID: 21792569
[TBL] [Abstract][Full Text] [Related]
2. A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.
van Dodewaard-de Jong JM; de Klerk JMH; Bloemendal HJ; Oprea-Lager DE; Hoekstra OS; van den Berg HP; Los M; Beeker A; Jonker MA; O'Sullivan JM; Verheul HMW; van den Eertwegh AJM
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1319-1327. PubMed ID: 28421240
[TBL] [Abstract][Full Text] [Related]
3. A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial.
van Dodewaard-de Jong JM; Bouman-Wammes EW; Bloemendal HJ; Verheul HMW; de Klerk JMH; van den Eertwegh AJM
Clin Nucl Med; 2017 Jun; 42(6):415-420. PubMed ID: 28263212
[TBL] [Abstract][Full Text] [Related]
4. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.
de Klerk JM; Zonnenberg BA; van het Schip AD; van Dijk A; Han SH; Quirijnen JM; Blijham GH; van Rijk PP
Eur J Nucl Med; 1994 Oct; 21(10):1114-20. PubMed ID: 7530199
[TBL] [Abstract][Full Text] [Related]
5. Systemic radionuclide therapy in pain palliation.
Liepe K; Runge R; Kotzerke J
Am J Hosp Palliat Care; 2005; 22(6):457-64. PubMed ID: 16323716
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.
O'Sullivan JM; Norman AR; McCready VR; Flux G; Buffa FM; Johnson B; Coffey J; Cook G; Treleaven J; Horwich A; Huddart RA; Parker CC; Dearnaley DP
Eur J Nucl Med Mol Imaging; 2006 Sep; 33(9):1055-61. PubMed ID: 16572306
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.
Tu SM; Mathew P; Wong FC; Jones D; Johnson MM; Logothetis CJ
J Clin Oncol; 2009 Jul; 27(20):3319-24. PubMed ID: 19414670
[TBL] [Abstract][Full Text] [Related]
8. High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone.
O'Sullivan JM; McCready VR; Flux G; Norman AR; Buffa FM; Chittenden S; Guy M; Pomeroy K; Cook G; Gadd J; Treleaven J; Al-Deen A; Horwich A; Huddart RA; Dearnaley DP
Br J Cancer; 2002 Jun; 86(11):1715-20. PubMed ID: 12087455
[TBL] [Abstract][Full Text] [Related]
9. Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases.
Küçük NO; Ibiş E; Aras G; Baltaci S; Ozalp G; Bedük Y; Canakci N; Soylu A
Ann Nucl Med; 2000 Aug; 14(4):239-45. PubMed ID: 11023023
[TBL] [Abstract][Full Text] [Related]
10. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Quirijnen JM; Blijham GH; van Rijk PP
J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 study of a high dose of 186Re-HEDP for bone pain palliation in patients with widespread skeletal metastases.
Pirayesh E; Amoui M; Mirzaee HR; Tabei F; Rakhsha A; Kalantari BA; Shafiei B; Assadi M; Asli IN
J Nucl Med Technol; 2013 Sep; 41(3):192-6. PubMed ID: 23918612
[TBL] [Abstract][Full Text] [Related]
13. (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.
Lam MG; Bosma TB; van Rijk PP; Zonnenberg BA
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1425-33. PubMed ID: 19319526
[TBL] [Abstract][Full Text] [Related]
14. Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.
Maxon HR; Schroder LE; Thomas SR; Hertzberg VS; Deutsch EA; Scher HI; Samaratunga RC; Libson KF; Williams CC; Moulton JS
Radiology; 1990 Jul; 176(1):155-9. PubMed ID: 1693784
[TBL] [Abstract][Full Text] [Related]
15. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
Buffa FM; Flux GD; Guy MJ; O'Sullivan JM; McCready VR; Chittenden SJ; Dearnaley DP
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1114-24. PubMed ID: 12761596
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.
Lin J; Sinibaldi VJ; Carducci MA; Denmeade S; Song D; Deweese T; Eisenberger MA
Urol Oncol; 2011; 29(6):670-5. PubMed ID: 19962920
[TBL] [Abstract][Full Text] [Related]
17. 186Re-HEDP for metastatic bone pain in breast cancer patients.
Lam MG; de Klerk JM; van Rijk PP
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S162-70. PubMed ID: 15118846
[TBL] [Abstract][Full Text] [Related]
18. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
De Klerk JM; Zonnenberg BA; Blijham GH; Van Het Schip AD; Hoekstra A; Han SH; Quirijnen JM; Van Dijk A; Van Rijk PP
Anticancer Res; 1997; 17(3B):1773-7. PubMed ID: 9179233
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
Liepe K; Kotzerke J
Nucl Med Commun; 2007 Aug; 28(8):623-30. PubMed ID: 17625384
[TBL] [Abstract][Full Text] [Related]
20. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
Liepe K; Runge R; Kotzerke J
J Cancer Res Clin Oncol; 2005 Jan; 131(1):60-6. PubMed ID: 15449184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
